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Background: In Gabon, antimalarial drugs are widely available
in both the private as well in the public sector and often self-
described (correctly and incorrectly) for the many febrile episodes
attributed to malaria. Insufﬁcient facilities to check the quality
of antimalarial drugs, poor patient knowledge about these drugs;
their relative high costs and the lack of appropriate regulatory
and legal actions by the government make these drugs attractive
for counterfeiters. Reports of poor quality and falsiﬁed drugs have
increased in the past decade and evidence that a considerable pro-
portion of drugs consumed in the developing world are of poor
quality (often with no active or wrong ingredients) is emerging.
Falsiﬁed drugs are an immediate threat for public health and have
led to a great number of deaths from untreated malaria. For Gabon,
there isno (published)dataabout thequalityof availableantimalar-
ial drugs.We hypothesize that poor-quality anti-malarial drugs are
prevalent in Gabon. The objective is to describe the quality of avail-
able antimalarial drugs and to determine the prevalence of poor
quality antimalarial drugs in the Republic of Gabon.
Methods & Materials: Methods: - Prospective observational
drug-quality ﬁeld survey. Packaging analysis and chemical drug-
quality analysis with the GPHF Minilab.
Main study outcomes: Theprimary outcome is the prevalence of
poor quality antimalarial drugs. Furthermore, the quality of avail-
able antimalarial drugswill be described. Secondary outcomes: The
proportion of outlets selling poor quality antimalarial drugs; the
availability and prevalence of antimalarial drugs that are no longer
recommended as ﬁrst or second-line treatment; the proportion of
different types of poor quality medicines and the risk indicators of
poor quality antimalarial drugs in terms of packaging or chemical
analysis.
Results: To be expected in January 2014 or latest February 2014
Conclusion: To be expected in January 2014
http://dx.doi.org/10.1016/j.ijid.2014.03.950
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Background: Globally, the issue of Multidrug Resistant Tuber-
culosis (MDR-TB) was acknowledged to being a threat to the
successful prevention and treatment of TB. In Malaysia, TB remains
a major health issue and incidence has been rising slowly for the
past decade indicating poor success rate in Malaysia’s current TB
control programme. Currently, very little epidemiological data can
be found regarding the situation of TB and MDR-TB in Malaysia.
Therefore, the objective of this retrospective study is to identify
the independent risk factors associated with MDR-TB in Malaysia.
Methods & Materials: 477 systematically randomized TB
patients from the Institute of RespiratoryMedicine (IPR)were sam-
pled based on the records of patients in 2010. Data were divided
based on four categories, sociodemographics, lifestyle and habits,
co-morbidities and TB case management.
Results: Among 477 patients sampled, 67.9% were male with
mean age 37.2 (SD 14.9). 30% of patients were foreign born with
the majority were from Myanmar (14.9%), Indonesia (9.4%) and
Bangladesh (2.7%). In multivariate logistic analysis, BCG Status
(AOR=0.292, 95%CI 0.13-0.67) was found to be a protective risk
factor while history of previous TB (AOR=4.36, 95%CI 1.80-10.56)
was a risk factor for MDR-TB.
Conclusion: Whilst history of previous TB is a commonly
acknowledged risk factor, the evidence of BCG as a protective factor
for MDR-TB indicates that BCG vaccination is still a viable preven-
tive measure. Therefore, this study recommends the continuation
of of neonatal BCG vaccination and further research should also
be carried out in order to allow the possiblity of reintroducing the
booster shot which was administered several years after the initial
vaccination. Research should not only focus on the cost effective-
ness of the practise but also on the long-term viability of booster
shot in protecting against TB and MDR-TB
http://dx.doi.org/10.1016/j.ijid.2014.03.951
